乙酰紫草素药理作用的研究进展
江周影1* 谢鹏发1* 郭嘉秀1 容家英1 唐星宇1 白琳2 邓鑫2
1.广西中医药大学瑞康临床医学院,广西南宁 530001;
2.广西中医药大学基础医学院,广西南宁 530001
Research progress on pharmacological action of acetyl shikonin
JIANG Zhouying1* XIE Pengfa1* GUO Jiaxiu1 RONG Jiaying1 TANG Xingyu1 BAI Lin2 DENG Xin2
1.Ruikang Clinical Medical College, Guangxi University of Chinese Medicine, Guangxi Zhuang Autonomous Region, Nanning 530001, China;
2.Basic Medical College, Guangxi University of Chinese Medicine, Guangxi Zhuang Autonomous Region, Nanning 530001, China
摘要 乙酰紫草素是由传统中草药紫草提取出的一种具有抗菌、抗感染、抗过敏、抗病毒、抗肿瘤等生物活性的萘醌类化合物。紫草及其衍生物乙酰紫草素在抗癌、抗病毒等研究中发挥着重要作用,有少数研究报道了乙酰紫草素对肝、心肌细胞毒性的不利影响,需进一步研究乙酰紫草素的毒性和药代动力学。本文主要对乙酰紫草素的理化性质、药理作用及机制与其潜在毒性进行总结和归纳,旨在为乙酰紫草素深入研究提供思路。
关键词 :
乙酰紫草素 ,
萘醌类化合物 ,
药理作用 ,
毒性作用 ,
研究进展
Abstract :Acetyl shikonin is a naphthoquinone compound with anti-bacterial, anti-inflammatory, anti-allergic, anti-viral, anti-tumor and other biological activities extracted from Chinese traditional herbal medicine Arnebiae Radix. Arnebiae Radix and its derivative acetyl shikonin have played an important role in anti-cancer and anti-viral studies. Only a few studies have reported the adverse effects of acetyl shikonin on liver and cardiomyocyte toxicity. Further studies on the toxicity and pharmacokinetics of acetyl shikonin are needed. In this paper, the physical and chemical properties, pharmacological action, mechanism and potential toxicity of acetyl shikonin are summarized and conclude, aiming to provide a reference for further study of acetyl shikonin.
Key words :
Acetyl shikonin
Naphthoquinone compounds
Pharmacological action
Toxic effects
Research progress
基金资助: 广西壮族自治区大学生创新创业训练计划项目(S202110600089);
广西中医药大学B类“桂派中医药传承创新团队”资助项目(2022B004)。
*具有同等贡献
通讯作者:
邓鑫(1976-),男,博士,教授,博士生导师;研究方向:中医药基础研究。
[1] 郑君婷,王文峰,李静,等.大黄素衍生物的合成及其抑制白血病细胞增殖作用的研究[J].中国实验血液学杂志,2013,21(1):53-56.
[2] 曾云,罗刚,杨文吉,等.乙酰紫草素注射液对S180荷瘤小鼠抑瘤作用研究[J].中药药理与临床,2008,24(1):22-23.
[3] 赵冉.紫草根有效成分β,β-二甲基丙烯酰阿卡宁和乙酰紫草素抑制结直肠癌的机制研究[D].郑州:郑州大学,2020.
[4] 吴广洲.Aurora-A基因干扰对人肺腺癌细胞体内外生物学行为的影响[D].苏州:苏州大学,2012.
[5] 郭晓青,郁强,范学顺.红景天苷联合iNOS shRNA对葡聚糖硫酸钠诱导的溃疡性结肠炎小鼠凝血功能及炎症因子水平的影响[J].中国临床药理学杂志,2021,37(8):988-992.
[6] 李蔚仑.萘醌色素的潜在毒性机理研究及潜在毒性评价[D].南宁:广西科技大学,2015.
[7] 宓伟,王志强,邱世翠,等.紫草体外抑菌作用研究[J].时珍国医国药,2007,18(9):2217.
[8] 叶佳.紫草化学成分及其抗耐药菌活性的研究[D].上海:复旦大学,2009.
[9] Sundaramoorthy NS,Mohan HM,Subramaniam S,et al. Ursolic acid inhibits colistin efflux and curtails colistin resistant Enterobacteriaceae [J]. AMB Express,2019,9(1):27.
[10] Andújar I,Ríos J,Giner R,et al. Pharmacological properties of shikonin—a review of literature since 2002 [J]. Planta Med,2013,79:1685-1697.
[11] Cheng YW,Chang CY,Lin KL,et al. Shikonin derivatives inhibited LPS-induced NOS in RAW 264.7 cells via downregulation of MAPK/NF-kappaB signaling [J]. J Ethnopharmacol,2008,120(2):264-271.
[12] 赵雪梅,王桂玲,费洪荣,等.紫草有效成分的提取及其抗炎作用研究[J].中药药理与临床,2008,24(4):36-38.
[13] 吴皓.右旋紫草素和紫草素促进大鼠肉芽组织增生的组织学研究[J].国外医学(中医中药分册),2003,25(3):163.
[14] Gong K,Li W. Shikonin,a Chinese plant-derived naphthoquinone,induces apoptosis in hepatocellular carcinoma cells through reactive oxygen species:a potential new treatment for hepatocellular carcinoma [J]. Free Radic Biol Med, 2011,51(12):2259-2271.
[15] Mao X,Rong YC,Hua LW,et al. Induction of apoptosis by shikonin through a ROS/JNK-mediated process in Bcr/ Abl-positive chronic myelogenous leukemia (CML) cells [J]. Cell Res,2008,18(8):879-888.
[16] Moon J,Koh SS,Malilas W,et al. Acetylshikonin induces apoptosis of hepatitis B virus X protein-expressing human hepatocellular carcinoma cells via endoplasmic reticulum stress [J]. Eur J Pharmacol,2014,735:132-140.
[17] 廖炜波,鲁弘骎,梁浩,等.乙酰紫草素对HCV复制的影响及其作用机制研究[J].内科,2019,14(2):137-141.
[18] 程珂举.乙酰紫草素对前列腺癌DNA损伤相关的氧化应激信号通路的调控[D].泰山:泰山医学院,2016.
[19] 赵景明,杨铁峥.乙酰紫草素对结肠癌细胞增殖、凋亡、侵袭及NF-κB通路的影响[J].中药材,2019,42(9):2168- 2172.
[20] 何茂旭,韩丽丽,王佩,等.乙酰紫草素诱导卵巢癌SKOV3细胞凋亡的实验研究[J].中国实验诊断学,2019,23(9):1632-1633.
[21] 薛德冬,李锐.乙酰紫草素对人结肠癌HCT116细胞增殖、凋亡及上皮间充质转化的影响[J].中成药,2017,39(2):401-404.
[22] Lim HM,Lee J,Nam MJ,et al. Acetylshikonin induces apoptosis in human colorectal cancer HCT-15 and LoVo cells via nuclear translocation of FOXO3 and ROS level elevation [J]. Oxid Med Cell Longev,2021,2021:6647107.
[23] 缪世坤,罗刚,周黎明.乙酰紫草素注射液对小鼠Lewis肺癌生长抑制的研究[J].四川生理科学杂志,2007,29(4):154-155.
[24] 曾云,罗刚,杨文吉,等.乙酰紫草素注射液对人胃癌细胞SGC-7901的抑制作用[J].四川生理科学杂志,2007, 29(4):155-157.
[25] Kyrou I,Randeva HS,Tsigos C,et al. Clinical problems caused by obesity [J]. In:Endotext [Internet],2018.
[26] Chang C,Dong R,Miyazaki A,et al. Human acyl-CoA:cholesterol acyltransferase (ACAT) and its potential as a target for pharmaceutical intervention against atherosclerosis [J]. Acta Biochim Biophys Sin (Shanghai),2006,38(3):151-156.
[27] An S,Park YD,Paik YK,et al. Human ACAT inhibitory effects of shikonin derivatives from Lithospermum erythrorhizon [J]. Bioorg Med Chem Lett,2007,17(4):1112- 1116.
[28] Gwon SY,Ji YA,Chang HC,et al. Lithospermum erythrorhizon suppresses high-fat diet-induced obesity,and acetylshikonin,a main compound of lithospermum erythrorhizon,inhibits adipocyte differentiation [J]. J Agric Food Chem,2012,60(36):9089-9096.
[29] Su M,Huang W,Zhu B,et al. Acetylshikonin from Zicao prevents obesity in rats on a high-fat diet by inhibiting lipid accumulation and inducing lipolysis [J]. PLoS One,2016, 11(1):e0146884.
[30] Kim HK,Della-Fera MA,Hausman DB,et al. Effect of clenbuterol on apoptosis,adipogenesis,and lipolysis in adipocytes [J]. J Physiol Biochem,2010,66:197-203.
[31] Zhang GP,Yang JX,Zhu YA. Study on antioxidant activity of lithospermum erythrorhizon in vitro [J]. J Wuhan Botanical Res,2007,25(5):490-493.
[32] 于明欣.紫草素对Hela细胞增殖抑制作用及血管平滑肌细胞保护作用研究[D].天津:天津医科大学,2014.
[33] 楼雅卿,陆道培,郭黔新.紫草醇提取物对动物实验性炎症过程的影响及毒性实验[J].北京医学院学报,1979, 11(2):83-86.
[34] Saifudin A,Tanaka K,Kadota S,et al. Protein tyrosine phosphatase 1B (PTP1B)-inhibiting constituents from the leaves of Syzygium polyanthum [J]. Planta Medica,2012,78(12):1378-1381.
[35] Li ZZ,Hong Z,Peng ZQ,et al. Acetylshikonin from Zicao ameliorates renal dysfunction and fibrosis in diabetic mice by inhibiting TGF-β1/Smad pathway [J]. Hum Cell,2018, 31(3):199-209.
[36] Ko FN,Lee YS,Kuo SC,et al. Inhibition on platelet activation by shikonin derivatives isolated from Arnebia euchroma [J]. Biochim Biophys Acta,1995,1268(3):329-334.
[37] Wang Y,Pan WL,Liang WC,et al. Acetylshikonin,a novel ache inhibitor,inhibits apoptosis via upregulation of heme oxygenase-1 expression in sh-sy5y cells [J]. Evid Based Complement Alternat Med,2013,2013:937370.
[38] Li Z,Yan Z,Xu C,et al. Acetylshikonin attenuates angiotensin Ⅱ-induced proliferation and motility of human brain smooth muscle cells by inhibiting Wnt/β-catenin signaling [J]. Human cell,2018,31(3):242-250.
[39] Ridker PN,McDermont WV. Hepatotoxicity due to comfrey herb tea [J]. Am J Med,1989,87(6):701.
[40] Bach N,Thung SN,Schaffner F. Comfrey herb tea-induced hepatic veno-occlusive disease [J]. Am J Med,1989,87(1): 97-99.
[41] 桂春,陈蒙华,林松,等.乙酰紫草素对培养大鼠心肌细胞的毒性作用[J].中药药理与临床,2010,26(6):33-36.
[42] 李蔚仑,李军生,黄国霞,等.乙酰紫草素的潜在毒性机理研究及毒性评价[J].食品工业,2015,36(5):174-178.
[1]
孙宜斌1 朱铭星2 刘跃洋3 赵若玮1 黄鸣清1 程再兴1 郑燕芳1 林彦翔1. 中药抗肝损伤机制的研究进展 [J]. 中国医药导报, 2023, 20(9): 38-40,45.
[2]
赵俊1 李霞1 田君健1 王鑫2 王雪飞2 李志刚1. 基于功能磁共振成像探讨针灸治疗肠易激综合征患者脑功能改变的研究进展 [J]. 中国医药导报, 2023, 20(8): 38-41.
[3]
陈盈盈 宋建忠 李杰 陈章浩 常军民. 刺糖化学成分及其生物活性研究进展 [J]. 中国医药导报, 2023, 20(7): 42-45,58.
[4]
方金旭1 刘璐2 戎茜兰1 李彬2. 火针加拔罐治疗带状疱疹的临床研究进展 [J]. 中国医药导报, 2023, 20(7): 46-49.
[5]
沈云博1 严博煜1 刘枫1 兰向宇1 张笑雪1 刘伟2. 肺癌癌因性疲乏病因病机及中医药治疗的研究进展 [J]. 中国医药导报, 2023, 20(6): 51-54.
[6]
徐亚慧1 殷建忠2 阮锡宇1 赵婷1 张俏1. 芒果苷调节糖脂代谢作用的研究进展 [J]. 中国医药导报, 2023, 20(6): 59-62.
[7]
邢维祖 麦勇猛 苏庆杰▲. 卒中后认知障碍非药物干预疗法的研究进展 [J]. 中国医药导报, 2023, 20(3): 50-54.
[8]
梁凤娇1 周霞2 王磊1 王祥煜1 张佳乐1. 基于CiteSpace音乐治疗卒中后抑郁的可视化分析 [J]. 中国医药导报, 2023, 20(20): 29-33,47.
[9]
林青青1 李智慧1 洪赟晢1 杨曙光2 余学庆2▲. 特发性肺纤维化肺康复的中西医研究进展 [J]. 中国医药导报, 2023, 20(20): 48-51.
[10]
刘印聪 马秀英 张玉亭 罗金波 肖安 王文学 耿嘉蔚. 粪菌移植治疗非酒精性脂肪性肝病的研究进展 [J]. 中国医药导报, 2023, 20(19): 45-48.
[11]
谢燕鹏 杨欢 刘建荣. 人工智能在辅助生殖领域中应用的研究进展 [J]. 中国医药导报, 2023, 20(19): 53-56.
[12]
史玉妮1 韩远山2 邹蔓姝1. 中药多糖治疗抑郁症的作用机制的研究进展 [J]. 中国医药导报, 2023, 20(18): 39-42.
[13]
张欣欣1 杨凤文2 李立强2. 中医药防治糖皮质激素性骨质疏松症的研究进展 [J]. 中国医药导报, 2023, 20(11): 53-56.
[14]
杨翔滟1 田茂露2 查艳1. 氧化三甲胺与慢性肾脏病及其并发症关系的研究进展 [J]. 中国医药导报, 2023, 20(11): 57-60.
[15]
戎茜兰1 刘璐2 方金旭1 李彬2. 慢性偏头痛的磁共振成像研究进展 [J]. 中国医药导报, 2023, 20(10): 37-41.